Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Paul Ausick | Jul 31, 2012 at 9:08 AM EDT

Forest Labs Continues to Reject Icahn, Who Continues to Fight Back

With the company’s annual shareholders’ meeting set for August 15, Forest Laboratories Inc. (NYSE: FRX) continues its proxy fight with…

Paul Ausick | Jul 31, 2012 at 7:36 AM EDT

Pfizer’s Profits Rise on Lower Revenues

Pfizer Inc. (NYSE: PFE) reported second-quarter adjusted earnings per share (EPS) of $0.62 and $15.06 billion in revenue this morning.…

Jon C. Ogg | Jul 30, 2012 at 8:18 AM EDT

FDA Complete Response Letter Takes a Big Bite Out of Hope (SLXP, PGNX)

The U.S. Food & Drug Administration has sent Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) a Complete…

247sam | Jul 27, 2012 at 11:23 AM EDT

Amarin Shares Fall Despite Regulatory OK

Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp.…

Jon C. Ogg | Jul 26, 2012 at 4:26 PM EDT

Amgen Earnings Reaction Close To All-Time Highs!

Amgen Inc. (NASDAQ: AMGN) today announced financial results for the second quarter of 2012. The biotech giant’s results showed a…

Jon C. Ogg | Jul 24, 2012 at 1:43 PM EDT

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment…

Jon C. Ogg | Jul 24, 2012 at 9:12 AM EDT

Carl Icahn Activist Letter to Forest Holders: A State of Crisis

Activist investing can sometimes be a bit like a tennis match to watch. And sometimes it can yield great profits…

Paul Ausick | Jul 24, 2012 at 7:21 AM EDT

Pfizer’s Alzheimer’s Drug Fails Trial

A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed…

Paul Ausick | Jul 20, 2012 at 12:10 PM EDT

Onyx Pharma Shares Halted Before FDA Approval

Shares of Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) were halted for about half an hour this morning pending an announcement from…

Paul Ausick | Jul 19, 2012 at 8:52 AM EDT

Walgreen Stock Jumps on New Deal with Express Scripts

While no details were provided, Walgreen Co. (NYSE: WAG) and Express Scripts Holding Co. (NASDAQ: ESRX) this morning announced a…

Paul Ausick | Jul 18, 2012 at 10:56 AM EDT

Top 10 U.S. Drugs for 2012 First Quarter

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for…

Paul Ausick | Jul 18, 2012 at 8:34 AM EDT

Abbott Labs Stung by Foreign Exchange Rate

Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but…

Paul Ausick | Jul 17, 2012 at 1:52 PM EDT

Icahn Blasts Forest Labs’ Directors

In an open letter to the board of directors of Forest Laboratories Inc. (NYSE: FRX), activist investor Carl Icahn doesn’t…

Paul Ausick | Jul 17, 2012 at 9:00 AM EDT

Currency Exchange Rates, One-Time Charges Hit J&J

Health care giant Johnson & Johnson (NYSE: JNJ) reported second-quarter earnings this morning, posting adjusted earnings per share (EPS) of…

Paul Ausick | Jul 12, 2012 at 10:06 AM EDT

Icahn Tries End-around in Proxy Fight with Forest Labs CEO/Chairman

Activist investor Carl Icahn has sent a letter to the non-executive members of the board of directors of Forest Laboratories…

1 … 315 316 317 318 319 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Forest Labs Continues to Reject Icahn, Who Continues to Fight Back

Pfizer’s Profits Rise on Lower Revenues

FDA Complete Response Letter Takes a Big Bite Out of Hope (SLXP, PGNX)

Amarin Shares Fall Despite Regulatory OK

Amgen Earnings Reaction Close To All-Time Highs!

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

Carl Icahn Activist Letter to Forest Holders: A State of Crisis

Pfizer’s Alzheimer’s Drug Fails Trial

Onyx Pharma Shares Halted Before FDA Approval

Walgreen Stock Jumps on New Deal with Express Scripts

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Icahn Blasts Forest Labs’ Directors

Currency Exchange Rates, One-Time Charges Hit J&J

Icahn Tries End-around in Proxy Fight with Forest Labs CEO/Chairman

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Forest Labs Continues to Reject Icahn, Who Continues to Fight Back

Pfizer’s Profits Rise on Lower Revenues

FDA Complete Response Letter Takes a Big Bite Out of Hope (SLXP, PGNX)

Amarin Shares Fall Despite Regulatory OK

Amgen Earnings Reaction Close To All-Time Highs!

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

Carl Icahn Activist Letter to Forest Holders: A State of Crisis

Pfizer’s Alzheimer’s Drug Fails Trial

Onyx Pharma Shares Halted Before FDA Approval

Walgreen Stock Jumps on New Deal with Express Scripts

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Icahn Blasts Forest Labs’ Directors

Currency Exchange Rates, One-Time Charges Hit J&J

Icahn Tries End-around in Proxy Fight with Forest Labs CEO/Chairman

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation